Merck, Schering Merger Puts Pressure On Regulators

By Jacqueline Bell

Law360, New York (March 09, 2009, 12:00 AM ET) -- Merck & Co.’s plan to merge with Schering-Plough Corp. in a $41.1 billion deal announced Monday is prompting questions over how antitrust regulators will tackle the second proposal in as many months to combine two pharmaceutical industry giants.

The Merck and Schering deal comes just six weeks after Pfizer Inc. revealed its own plans to take over Wyeth Inc. in a deal valued at $68 billion.

Many U.S. drugmakers are facing patent expirations of a number of their blockbuster drugs in the next few years, and...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles